Literature DB >> 30916803

MYH9-related disease mutations cause abnormal red blood cell morphology through increased myosin-actin binding at the membrane.

Alyson S Smith1, Kasturi Pal1, Roberta B Nowak1, Anastasiya Demenko1, Carlo Zaninetti2, Lydie Da Costa3,4,5,6, Remi Favier7, Alessandro Pecci2, Velia M Fowler1,8.   

Abstract

MYH9-related disease (MYH9-RD) is a rare, autosomal dominant disorder caused by mutations in MYH9, the gene encoding the actin-activated motor protein non-muscle myosin IIA (NMIIA). MYH9-RD patients suffer from bleeding syndromes, progressive kidney disease, deafness, and/or cataracts, but the impact of MYH9 mutations on other NMIIA-expressing tissues remains unknown. In human red blood cells (RBCs), NMIIA assembles into bipolar filaments and binds to actin filaments (F-actin) in the spectrin-F-actin membrane skeleton to control RBC biconcave disk shape and deformability. Here, we tested the effects of MYH9 mutations in different NMIIA domains (motor, coiled-coil rod, or non-helical tail) on RBC NMIIA function. We found that MYH9-RD does not cause clinically significant anemia and that patient RBCs have normal osmotic deformability as well as normal membrane skeleton composition and micron-scale distribution. However, analysis of complete blood count data and peripheral blood smears revealed reduced hemoglobin content and elongated shapes, respectively, of MYH9-RD RBCs. Patients with mutations in the NMIIA motor domain had the highest numbers of elongated RBCs. Patients with mutations in the motor domain also had elevated association of NMIIA with F-actin at the RBC membrane. Our findings support a central role for motor domain activity in NMIIA regulation of RBC shape and define a new sub-clinical phenotype of MYH9-RD.
© 2019 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30916803      PMCID: PMC6510596          DOI: 10.1002/ajh.25472

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  58 in total

1.  Rod mutations associated with MYH9-related disorders disrupt nonmuscle myosin-IIA assembly.

Authors:  Josef D Franke; Fan Dong; Wayne L Rickoll; Michael J Kelley; Daniel P Kiehart
Journal:  Blood       Date:  2004-08-31       Impact factor: 22.113

Review 2.  Feisty filaments: actin dynamics in the red blood cell membrane skeleton.

Authors:  David S Gokhin; Velia M Fowler
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

3.  A new feature of the MYH9-related syndrome: chronic transaminase elevation.

Authors:  Rémi Favier; Analisa DiFeo; Nathalie Hezard; Monique Fabre; Pierre Bedossa; John A Martignetti
Journal:  Hepatology       Date:  2012-11-27       Impact factor: 17.425

4.  Selective solubilization of proteins and phospholipids from red blood cell membranes by nonionic detergents.

Authors:  J Yu; D A Fischman; T L Steck
Journal:  J Supramol Struct       Date:  1973

5.  Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly.

Authors:  M J Kelley; W Jawien; T L Ortel; J F Korczak
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

6.  Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A.

Authors:  Yingfan Zhang; Mary Anne Conti; Daniela Malide; Fan Dong; Aibing Wang; Yelena A Shmist; Chengyu Liu; Patricia Zerfas; Mathew P Daniels; Chi-Chao Chan; Elliot Kozin; Bechara Kachar; Michael J Kelley; Jeffrey B Kopp; Robert S Adelstein
Journal:  Blood       Date:  2011-09-08       Impact factor: 22.113

7.  Tropomodulin 1 controls erythroblast enucleation via regulation of F-actin in the enucleosome.

Authors:  Roberta B Nowak; Julien Papoin; David S Gokhin; Carla Casu; Stefano Rivella; Jeffrey M Lipton; Lionel Blanc; Velia M Fowler
Journal:  Blood       Date:  2017-07-20       Impact factor: 22.113

Review 8.  MYH9-related platelet disorders.

Authors:  Karina Althaus; Andreas Greinacher
Journal:  Semin Thromb Hemost       Date:  2009-04-30       Impact factor: 4.180

9.  Myosin IIA associates with NK cell lytic granules to enable their interaction with F-actin and function at the immunological synapse.

Authors:  Keri B Sanborn; Gregory D Rak; Saumya Y Maru; Korey Demers; Analisa Difeo; John A Martignetti; Michael R Betts; Rémi Favier; Pinaki P Banerjee; Jordan S Orange
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

10.  The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition.

Authors:  Y Chen; S Boukour; R Milloud; R Favier; B Saposnik; N Schlegel; A Nurden; H Raslova; W Vainchenker; M Balland; P Nurden; N Debili
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

View more
  5 in total

1.  Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling.

Authors:  Yunhao Wu; Xiu Yu; Yuwei Wang; Yalin Huang; Jiahui Tang; Shuaishuai Gong; Siyu Jiang; Yuanli Xia; Fang Li; Boyang Yu; Yuanyuan Zhang; Junping Kou
Journal:  Acta Pharm Sin B       Date:  2021-09-22       Impact factor: 14.903

2.  Reduced platelet forces underlie impaired hemostasis in mouse models of MYH9-related disease.

Authors:  Juliane Baumann; Laura Sachs; Oliver Otto; Ingmar Schoen; Peter Nestler; Carlo Zaninetti; Martin Kenny; Ruth Kranz; Hendrik von Eysmondt; Johanna Rodriguez; Tilman E Schäffer; Zoltan Nagy; Andreas Greinacher; Raghavendra Palankar; Markus Bender
Journal:  Sci Adv       Date:  2022-05-18       Impact factor: 14.957

3.  Nanoscale dynamics of actin filaments in the red blood cell membrane skeleton.

Authors:  Roberta B Nowak; Haleh Alimohamadi; Kersi Pestonjamasp; Padmini Rangamani; Velia M Fowler
Journal:  Mol Biol Cell       Date:  2022-01-12       Impact factor: 3.612

4.  Myh9 R702C is associated with erythroid abnormality with splenomegaly in mice.

Authors:  Takeshi Kanematsu; Nobuaki Suzuki; Shogo Tamura; Atsuo Suzuki; Yuichi Ishikawa; Akira Katsumi; Hitoshi Kiyoi; Hidehiko Saito; Shinji Kunishima; Tetsuhito Kojima; Tadashi Matsushita
Journal:  Nagoya J Med Sci       Date:  2021-02       Impact factor: 1.131

5.  Identification of Transferrin Receptor 1 (TfR1) Overexpressed in Lung Cancer Cells, and Internalization of Magnetic Au-CoFe2O4 Core-Shell Nanoparticles Functionalized with Its Ligand in a Cellular Model of Small Cell Lung Cancer (SCLC).

Authors:  Rocío Villalobos-Manzo; Emmanuel Ríos-Castro; José Manuel Hernández-Hernández; Goldie Oza; Mauricio A Medina; José Tapia-Ramírez
Journal:  Pharmaceutics       Date:  2022-08-17       Impact factor: 6.525

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.